APEIRON Biologics AG Closes Regional License Agreement for Antibody-based Immunotherapy
Apeiron today announced the closing of a transaction with Paladin Labs Inc. (Canada) in its ongoing initiative to out-license APN311, an antibody-based immunotherapy in development for the treatment of children with high-risk neuroblastoma.
Below, we ask for your consent to the use of non-technically necessary cookies so that we can provide you with the best possible service on our website.
In accordance with Art 49 para 1 lit a GDPR, your consent also includes the transfers to recipients in insecure third countries, such as the USA in particular, which are described in detail in the data protection information.
You can refuse the storage of cookies that are not technically necessary in advance under "Customize cookies" or revoke your consent to storage at any time in your browser settings. By clicking on the "I agree" button, you consent to the storage of all non-technically necessary cookies.
The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
The technical storage or access that is used exclusively for statistical purposes.The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.